AUG 02, 2022 8:00 AM PDT

Brain Derived Exosomes; a non-invasive look inside the brain

SPONSORED BY: NanoSomiX, Inc.

Exosomes are small extracellular vesicles about the size of influenza and corona viruses and have been making news for several years due to their diagnostic and therapeutic potential.  Cells throughout the body produce exosomes and release them into the extracellular spaces. Originally thought to be a process to dispose of cellular waste, it is now known that exosomes represent a cell-to-cell communication network, carrying proteins, RNAs, and other biomolecules from the cell of origin to other cells locally and through the bloodstream to distant organs.  Due to their presence in blood and other biological fluids, the detection and isolation of exosomes has contributed to significant advancement in liquid biopsies for diagnosis and research.

A characteristic of exosomes is that they are able to cross the Blood Brain Barrier allowing for selective capture of brain-derived exosomes (BDE) from the blood. This creates the opportunity to evaluate changes in brain cells through a minimally invasive blood test.  Because exosomes are derived from a mother cell, the exosome membrane bears the molecular characteristics of that cell. As a result, BDE can be captured from blood samples using antibodies directed to specific surface molecules expressed on the parent brain cell.  Studies have shown that in progressive diseases such as Alzheimer’s and Parkinson’s, changes in blood BDE biomarkers can be detected years prior to and after the onset of observable clinical symptoms. Thus, even subclinical changes that occur in the brain cells of origin may be detected by BDE biomarkers before overt disease or progression in some cases.  In other clinical settings such as stroke and traumatic brain injury (TBI), analysis of BDE changes and associated biomarkers can provide a minimally invasive means to track the progression or regression of resulting damage or trauma to the brain. Moreover, with the advances in molecular biomarkers and sensitive selective BDE assays, this form of liquid biopsy has enormous potential in basic and clinical research for multiple types of brain trauma, dysfunction and disease.  As exosomes are highly stable while in circulation and under laboratory conditions, they can be used to identify changes from a normal state, monitor disease progression, and measure a therapeutic response.  Our company, NanoSomiX, has worked with both academic institutions and pharmaceutical companies on projects that range from new biomarker identification and clinical research to potential companion diagnostics. 

As our research uses sample sets from a variety of neurological disorders and controls, we have made significant research and clinical observations in working with BDEs.  For example, we now know that neuron-derived exosomes (NDE) in the blood under normal conditions vary greatly from person to person, but the number is generally stable within an individual over extended times. It is also clear that NDE levels can change dramatically in response to external traumatic clinical events.  This suggests that disease progression or therapeutic responses may be monitored in an individual by assessment of types of blood BDE.  NanoSomiX is also now working on BDE subtypes including neurotransmitter-specific dopaminergic and serotonergic NDEs, astrocyte-derived exosomes (ADE) and oligodendrocyte-derived exosomes (ODE). How changes in these various types of circulating neurologic exosomes fluctuate with disease and alterations in the brain is a major focus of our research and collaborations.

If you are interested to see how analysis of BDE may help with your research or clinical project, please contact vclements@nanosomix.com.  Our flexibility allows us to work with your team on a fee-for-service basis or collaboratively on a longer-term project.  Together, let’s see how BDEs can enhance your work.

About the Sponsor
NanoSomiX, Inc. is dedicated to providing insight to researchers and clinicians through the detection and management of neurological disorders via a routine blood test. The company’s proprietary technology is based on the identification and enrichment of brain-derived exosomes (BDE) from blood and the analysis of associated proteins. All testing is performed in a CLIA-approved laboratory in Irvine, Calif. The company is headquartered in Aliso Viejo, Calif. For more information, see www.nanosomix.com.
You May Also Like
JUL 20, 2022
Neuroscience
Stress Transmitter Wakes Up the Sleeping Brain Over 100 Times Per Night
JUL 20, 2022
Stress Transmitter Wakes Up the Sleeping Brain Over 100 Times Per Night
A study published in Nature Neuroscience reported that the stress hormone and transmitter noradrenaline wakes up the hum ...
AUG 04, 2022
Clinical & Molecular DX
Artificial Intelligence Shows Promise in Diagnosing Strokes
AUG 04, 2022
Artificial Intelligence Shows Promise in Diagnosing Strokes
Quick identification and intervention is critical in successfully treating a stroke. During a stroke, blood supply to th ...
AUG 11, 2022
Cannabis Sciences
If You're Over 40 and You Like THC and CBD, Read This
AUG 11, 2022
If You're Over 40 and You Like THC and CBD, Read This
Are there risks to ingesting cannabis if you're over 40? Get the details here.
AUG 16, 2022
Neuroscience
A Common Denominator Among All Forms of ALS is Revealed
AUG 16, 2022
A Common Denominator Among All Forms of ALS is Revealed
ALS (amyotrophic lateral sclerosis) is a motor neuron disease, which gradually causes a loss of movement. Eventually, pa ...
AUG 24, 2022
Cannabis Sciences
Can Cannabis Help You Diet?
AUG 24, 2022
Can Cannabis Help You Diet?
Can cannabis actually help with weight loss? Here's the details
SEP 21, 2022
Neuroscience
What We Can Learn From Brain Asymmetry
SEP 21, 2022
What We Can Learn From Brain Asymmetry
A study published in eLife examined the subtle differences in functional organization between the left and right side of ...
Loading Comments...